L-Carnitine
An old post-heart-attack literature that pooled twice with different answers, and a fat-burning claim with no convincing evidence behind it.
C+
Evidence grade
C
Worth it
$15-25/month
Typical cost
DoseThe studied supplemental range is about 2 g/day; the post-heart-attack re-analysis found no significant benefit at maintenance doses above 2 g/day, and TMAO production climbs with dose. The fertility trials used carnitines in the 2 to 3 g/day range, alone or with the acetyl form.
BasisThe best data are old and targeted.
L-carnitine is the plain form of carnitine, the compound that shuttles fatty acids into mitochondria to be burned. We grade L-Carnitine C+ on evidence and C for worth-it at about $15-25 per month.
Questions
Answers come straight from this record's graded evidence.
L-carnitine vs acetyl-L-carnitine: are they the same?
No: they are two forms of carnitine with different evidence bases, which is why this library grades them as separate records. Plain L-carnitine (C+ evidence, C worth-it) carries the older targeted literature at about 2 g a day, including the post-heart-attack work and fertility trials. The acetyl form, ALCAR (B- evidence, C+ worth-it), crosses into the brain more readily and carries the cognition and fatigue literature at 1.5 to 3 g a day.
the forms convert into each other in the body, which is why sellers treat them as interchangeable; the trial record does not, and neither do the grades. Both share the TMAO pathway caution that sits at the centre of the L-carnitine record's safety notes.
What it does
L-carnitine is the plain form of carnitine, the compound that shuttles fatty acids into mitochondria to be burned. This record grades the plain form only. Acetyl-L-carnitine (ALCAR, graded B- in this library) is a separate record with a cognition-led trial base; the forms share a name and almost nothing else, and neither grade borrows from the other. The plain form's trial base is exercise, fatigue, male fertility, and an older cardiology literature from the years after a heart attack.
What the research says
Lowers death and arrhythmia risk after a heart attack
Evidence: emerging. A 2013 Mayo Clinic Proceedings meta-analysis (13 trials, 3,629 patients) associated L-carnitine with 27 percent lower all-cause mortality, 65 percent fewer ventricular arrhythmias, and 40 percent less angina; heart failure and reinfarction trends were not significant. A later dose-focused re-analysis (5 trials, 3,108 patients) found no significant benefit at maintenance doses above 2 g/day. The trials are small and span decades.
Improves sperm motility in male infertility
Evidence: emerging. An eight-trial meta-analysis found carnitines improve total and progressive sperm motility and morphology, with no effect on concentration and no demonstrated effect on pregnancy rates; a 2025 Nutrients systematic review of 50 supplement trials found no supplement improved pregnancy or live birth, with the certainty of evidence rated low.
Burns fat and causes weight loss (the popular claim)
Evidence: weak. The NIH Office of Dietary Supplements position is that no convincing evidence shows L-carnitine causes weight loss. In healthy young omnivores, who are already carnitine replete, the exercise literature is inconsistent.
The best data are old and targeted. A 2013 Mayo Clinic Proceedings meta-analysis of 13 trials (3,629 patients) associated L-carnitine after a heart attack with 27 percent lower all-cause mortality, 65 percent fewer ventricular arrhythmias, and 40 percent less angina, with heart failure and reinfarction trends not significant; a later dose-focused re-analysis (5 trials, 3,108 patients) found no significant benefit at maintenance doses above 2 g/day, which is why the signal grades as a lead rather than a finding. Male fertility shows improved sperm motility without a demonstrated pregnancy effect. The popular fat-burning claim has no convincing evidence behind it. Small, decades-spanning trials pooled twice with different answers are the C+ shape.
Is it worth it?
Evidence (C+) sits below the evidence bar for the ranking, which caps the worth-it grade at C+; the derived value at about $20 a month lands at C. The post-heart-attack signal belongs to a supervised setting and an old trial base, not to a general-purpose purchase.
Typical cost
$15-25/month
Common form, not a brand recommendation
Dosage context emerging
The studied supplemental range is about 2 g/day; the post-heart-attack re-analysis found no significant benefit at maintenance doses above 2 g/day, and TMAO production climbs with dose. The fertility trials used carnitines in the 2 to 3 g/day range, alone or with the acetyl form.
The worth-it ranking
L-Carnitine sits outside the worth-it ranking of 38.
L-Carnitine sits outside that ranking of 38. The leaders below clear an evidence floor of B- before price counts at all, so cheap alone never earns a rank.
- 1AWorth itCreatine evidence A-~$5-10/mo
- 2AWorth itCaffeine evidence B+~$5-10/mo
- 3AWorth itVitamin D evidence B~$5-8/mo
When the evidence moves a grade, this ranking moves with it. Thursday is where you hear it first.
Safety notes
The safety centre is the TMAO pathway: gut bacteria convert carnitine to TMA, which the liver converts to TMAO, a compound associated with cardiovascular risk in cohort data (the Cleveland Clinic work published in Nature Medicine is the anchor study). The association is stated as an association; the red meat data behind it carry a saturated fat confound. Still, the compound sold for heart health carries a long-term, dose-related question mark over exactly that system, which is one reason this record caps at the studied 2 g/day range rather than the 3 g/day and above range where TMAO production climbs. Common costs are nausea, cramps, and a fishy body odor at higher doses. Talk to your doctor. This page is information, not medical advice.
Changelog
Last updated 2026-11-04
- 2026-11-04|Initial grading: Research's weekly deep dive of 2026-11-02 (L-carnitine section), integrated on its dated queue slot (combined grading-order ruling: Wed Nov 4). Standalone record per the ruling's shape call (the K-form precedent): the plain form's exercise, fatigue, fertility, and cardiology trial base diverges from ALCAR's cognition base, so the forms are graded separately and neither grade borrows from the other.
The week's longevity and biohacking news.
Every story graded against the evidence. Free. Unsubscribe anytime.
The week's longevity and biohacking news. Every story graded against the evidence. Free. Unsubscribe anytime.
Every grade follows a published rubric. Sponsors do not influence findings or grades.